Establishment of a biomarker model to predict the efficacy and recurrence risk of targeted drugs combined mFOLFOXIRI in the treatment of unresectable advanced rectal cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300074030

Enrollment

Unknown

Registered

2023-07-27

Start date

2021-11-01

Completion date

Unknown

Last updated

2023-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Case series:No

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with unresectable locally advanced and metastatic rectal cancer who are clinically appropriate for cetuximab or bevacizumab combined with mFOLFOXIRI.

Exclusion criteria

Exclusion criteria: 1.Patients with unresectable locally advanced and metastatic rectal cancer who are not clinically appropriate for cetuximab or bevacizumab combined with mFOLFOXIRI. 2.Other conditions that the investigator considers inappropriate for inclusion.

Design outcomes

Primary

Measure	Time frame
Complete remission rate;Biomarker;	—

Secondary

Measure	Time frame
Margin-free (R0) resection rate;3y-OS, overall survival;3y-DFS, disesease free survival;QOL, quality of life;mrTRG,MRI-tumor regression grade;Bowel and sexual functions;Distant metastasis rate;Organ preservation rate;	—

Countries

China

Contacts

Public ContactXiaodong Wang

Peking University Shougang Hospital

xdwang2000@163.com+86 10 5783 0284

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026